Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 31, 2024 04:47 ET | Source: Research and Markets

2 Day Virtual Variations to Marketing Authorisations Training Course

Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Variations to Marketing Authorisations Training Course" conference has been added to ResearchAndMarkets.com's offering. It is a key post-marketing...
May 31, 2023 09:19 ET | Source: Pharmazz, Inc.

Pharmazz, Inc. Announces Marketing Approval of Sovateltide in India for Acute Cerebral Ischemic Stroke Patients

The proportion of acute cerebral ischemic stroke patients with the mRS of 0-2 on day 90 post-randomization was statistically significant (p=0.002) Sovateltide is a first-in-class drug that...
May 02, 2023 08:03 ET | Source: Research and Markets

Variations to Marketing Authorisations Training Course: Optimising Regulatory Procedures to Achieve Faster Approval

Dublin, May 02, 2023 (GLOBE NEWSWIRE) -- The "Variations to Marketing Authorisations Training Course" conference has been added to ResearchAndMarkets.com's offering. It is a key post-marketing...
December 28, 2021 18:15 ET | Source: The Rosen Law Firm PA

OWLT LOSS ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Owlet, Inc. Investors with Losses to Secure Counsel Before Important January 18 Deadline in Securities Class Action – OWLT

NEW YORK, Dec. 28, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds: (a) purchasers of the securities of Owlet, Inc. (NYSE: OWLT) between March 31, 2021 and...
August 06, 2021 04:53 ET | Source: Research and Markets

Global Orphan Drugs Market Report 2021-2026 Featuring Market Leaders - AbbVie, Eli Lilly, Johnson & Johnson, Merck & Co., Pfizer and Sanofi-Aventis

Dublin, Aug. 06, 2021 (GLOBE NEWSWIRE) -- The "Global Markets for Orphan Drugs" report has been added to ResearchAndMarkets.com's offering. The Global Orphan Drug Market is Set to Grow to $191...
January 12, 2021 09:28 ET | Source: Research and Markets

Global Rare Diseases Drug Development, Clinical Trials and the Regulatory Landscape Report 2021 with Analysis of Trends and Characteristics of Clinical Trials from 1999-2018

Dublin, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The "Drug Development in Rare Diseases: Focus on Clinical Trials and the Regulatory Landscape" report has been added to ResearchAndMarkets.com's offering....
April 30, 2020 20:14 ET | Source: Telix Pharmaceuticals Limited

Telix Pharmaceuticals submits European marketing authorisation application for prostate cancer imaging product

MELBOURNE, Australia and LIÈGE, Belgium, May 01, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has submitted a marketing...
January 02, 2020 01:00 ET | Source: INNATE PHARMA

The European Medicines Agency Accepts the Regulatory Submission for Lumoxiti in Relapsed or Refractory Hairy Cell Leukemia

MARSEILLE, France, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the European Medicines...
October 31, 2018 08:00 ET | Source: IntelGenx Technologies Corp.

The Spanish Agency of Medicines and Medical Devices Grants Marketing Authorization of RIZAPORT®

SAINT LAURENT, Quebec, Oct. 31, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announced that its commercialization partner for...